MedTrace Logo

AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC)

NCT05667350 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 492

Last updated 2022-12-30

No results posted yet for this study

Summary

ASCEND-BTC is a prospective, multi-center, observational study aimed at detecting early biliary tract cancer by combined assays of serum protein and cell-free DNA (cfDNA) methylation. The study will enroll approximately 492 participants diagnosed with biliary tract cancer and benign diseases.

Conditions

  • Biliary Tract Cancer

Interventions

OTHER

Blood drawing

Blood drawing before anti-cancer therapy

OTHER

Blood drawing

Blood drawing before radical treatment

Sponsors & Collaborators

  • Guangzhou Burning Rock Bioengineering Co., Ltd

    collaborator UNKNOWN

  • Eastern Hepatobiliary Surgery Hospital

    lead OTHER

Principal Investigators

  • Xiaoqing Jiang, MD/PhD · Eastern Hepatobiliary Surgery Hospital

  • Bin Li, MD/PhD · Eastern Hepatobiliary Surgery Hospital

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-28
Primary Completion
2023-12-31
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05667350 on ClinicalTrials.gov